Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of mirtazapine powder in China. Welcome to wholesale bulk high quality mirtazapine powder for sale here from our factory. Good service and reasonable price are available.
Mirtazapine Powder is a white crystalline chemical substance with the chemical formula C ₁₇ H ₁₉ N ∝, molecular weight 265.35 g/mol, CAS accession number 61337-67-5. It belongs to the tetracycline class of antidepressants (TeCA) and is also the world's first norepinephrine and specific 5-hydroxytryptamine antidepressant (NaSSA), exerting antidepressant effects by regulating multiple neurotransmitters. It can enhance the neurotransmission of norepinephrine (NE) and serotonin (5-HT), antagonize central alpha ₂ receptors, inhibit negative feedback, promote NE release, specifically block 5-HT ₂ and 5-HT ∝ receptors, regulate 5-HT function, and enhance antidepressant effects. Antihistamine (H ₁) receptors can cause drowsiness and are commonly used to improve insomnia. Anti 5-HT ₂/5-HT ∝ receptors can alleviate anxiety, nausea, and improve appetite.
Our product
 |
 |
 |
 |
| Product Name | Mirtazapine Powder | Mirtazapine Tablets 30mg |
| Product Type | Powder | Tablet |
| Product Purity | ≥99% | ≥99% |
| Product Specifications | 100g/1kg/etc. | 15mg/30mg |
| Product Form | Organic synthesis | Take Orally |
Mirtazapine COA
 |
||
| Certificate of Analysis | ||
| Compound name | Mirtazapine | |
| Grade | Pharmaceutical grade | |
| CAS No. | 85650-52-8 | |
| Quantity | 337.3kg | |
| Packaging standard | 25kg/drum | |
| Manufacturer | Shaanxi BLOOM TECH Co., Ltd | |
| Lot No. | 202501090047 | |
| MFG | Jan 9th 2025 | |
| EXP | Jan 8th 2028 | |
| Structure |
|
|
| Item | Enterprise standard | Analysis result |
| Appearance | White or almost white powder | Conformed |
| Water content | ≤5.0% | 0.49% |
| Loss on drying | ≤1.0% | 0.30% |
| Heavy Metals | Pb≤0.5ppm | N.D. |
| As≤0.5ppm | N.D. | |
| Hg≤0.5ppm | N.D. | |
| Cd≤0.5ppm | N.D. | |
| Purity (HPLC) | ≥99.0% | 99.90% |
| Single impurity | <0.8% | 0.49% |
| Total microbial count | ≤750cfu/g | 80 |
| E. Coli | ≤2MPN/g | N.D. |
| Salmonella | N.D. | N.D. |
| Ethanol (by GC) | ≤5000ppm | 500ppm |
| Storage | Store in a sealed, dark, and dry place below 2-8°C | |
|
|
||
|
|
||
Mirtazapine Powder, also known as Mirtazapine, is a psychoactive ingredient with significant application value in the medical field. Its unique pharmacological mechanism of action makes it play a key role in the treatment of various mental disorders and related symptoms, and it also has specific uses in the production of pharmaceutical preparations and other fields.
Core medical use: the main drug for antidepressant treatment
Mirtazapine powder, as a tetracyclic antidepressant (NaSSA class), is the world's first antidepressant drug that regulates neurotransmitters through a dual mechanism. Its core mechanism of action includes:
Alpha ₂ receptor antagonism: Blocking central presynaptic membrane alpha ₂ receptors, relieving negative feedback inhibition of norepinephrine (NE) release, significantly enhancing adrenergic nerve conduction.
5-hydroxytryptamine receptor regulation: Specifically blocks 5-HT ₂ and 5-HT ∝ receptors, allowing 5-hydroxytryptamine (5-HT) to primarily act on 5-HT-A receptors, optimizing serotonin function.
Histamine H ₁ receptor antagonism: produces sedative effects and improves sleep quality.
Approved by the US FDA in 1996, it has been used in over 70 countries for the treatment of major depressive disorder (MDD).
The German S3 guideline states that its relief rate for symptoms such as lack of pleasure, psychomotor inhibition, early awakening, and weight loss is 68% -75%.
Compared to SSRI drugs such as fluoxetine, Mirtazapine Powder has a faster onset of action (1-2 weeks) and has less impact on sexual function.
Collaborative treatment with accompanying symptoms
Anxiety disorder with insomnia: Improving sleep latency, duration, and quality through sedative effects, especially suitable for patients with comorbid depression and anxiety.
Post traumatic stress disorder (PTSD): Some guidelines recommend it as an adjuvant therapy drug to alleviate emotional fluctuations and sleep disorders.
Cancer related symptoms:
Improve chemotherapy-induced nausea and vomiting (CINV), with significant 5-HT receptor antagonism.
Relieve appetite loss and promote weight recovery in cancer patients, with clinical trials showing an average weight gain of 2.3kg/month.
Special populations and indications expansion
The preferred medication for elderly patients
Dose adjustment: The German FORTA list classifies it as Class C (efficacy to risk ratio needs to be closely monitored), with a recommended initial dose of 7.5-15mg/day and a maximum dose not exceeding 30mg/day.
Advantage:
The cognitive side effects are relatively mild, making it suitable for sleep disorder patients with concomitant dementia.
Almost no anticholinergic effect, reducing the risk of dry mouth, constipation, urinary retention, etc.
The cardiovascular impact is minimal, and hypertensive patients have good tolerance.
Adjuvant treatment for patients with chronic diseases
Chronic kidney disease (CKD): To improve appetite loss and malnutrition in patients with end-stage kidney disease, the dosage needs to be adjusted according to creatinine clearance rate (such as reducing by 50% when GFR<30ml/min).
Congestive heart failure: Relieve appetite loss and nausea caused by the disease, but monitor the risk of orthostatic hypotension.
Liver failure: Patients with liver dysfunction due to CYP3A4 metabolism need to extend the dosing interval (such as once every 48 hours).
Application of Veterinary Medicine
Cat and dog appetite suppressants:
Dosage: 0.6mg/kg orally for cats, once every 3 days; Dogs are classified by weight (<9kg 3.75mg/day, 9-23kg 7.5mg/day,>23kg 15mg/day).
Indications: Postoperative loss of appetite, chronic kidney disease, liver tumors, pyometra, etc.
Antiemetic treatment: Used in combination with ondansetron to alleviate chemotherapy-induced nausea and vomiting, with an effective rate increased to 82%.
Clinical Practice of Off label Use
1. Treatment of Simple Insomnia
Dosage: 3.75-7.5mg/day (much lower than the antidepressant dose), taken before bedtime.
Mechanism: Shorten sleep onset time (average reduction of 22 minutes) and prolong total sleep time (increase of 1.1 hours) through H ₁ receptor antagonism.
Evidence: The German S3 guidelines recommend second-line medication for patients with SSRI drug intolerance.
2. Treatment of chronic pruritus
Dosage: 15-30mg/day, treatment course 4-8 weeks.
indication:Inflammatory skin disease associated itching (such as atopic dermatitis).Pruritus due to cholestasis.Itching related to renal failure.
Mechanism: Indirectly relieving itching by inhibiting 5-HT3 receptors to reduce itch signal transmission and improving sleep quality.
3. Adjuvant treatment for substance abuse disorders
Methamphetamine addiction: Animal experiments have shown that it can reduce drug seeking behavior, and clinical studies are exploring its role in reducing withdrawal symptoms and improving remission rates.
Alcohol dependence: Used in combination with naltrexone to improve sleep and appetite, and reduce relapse rates.
Pharmacokinetic characteristics and medication guidance
Absorption and metabolism
Oral bioavailability: 50% (food does not affect absorption).
Peak time: 2 hours (fasting), 4 hours (after meals).
Half life: 20-40 hours (with significant individual differences), requiring daily medication at a fixed time.
Metabolic pathway:
Mainly metabolized by CYP2D6 and CYP3A4 enzymes, producing demethylazepine (active metabolite).
75% is excreted through urine and 25% through feces.
Principle of dose adjustment
Initial treatment: 15mg/day, taken before bedtime.
Dose escalation: Increase by 15mg every 1-2 weeks, with a maximum dose of 45mg per day.
Special populations:
Elderly individuals: initial dose of 7.5mg/day, maximum dose of 15mg/day.
Liver and kidney dysfunction: When creatinine clearance rate is less than 30ml/min, the dose is halved; Patients with Child Pugh C liver function are prohibited from using it.
Adverse reactions and risk management
Common adverse reactions (incidence>10%)
Central nervous system: drowsiness (54%), dizziness (12%).
Metabolic system: increased appetite (32%), weight gain (average 2.8kg/month).
Digestive system: dry mouth (11%), constipation (8%).
Serious adverse reactions (incidence rate<1%)
Hematological system: Neutropenia (0.3%) requires regular monitoring of blood routine.
Cardiovascular system: orthostatic hypotension (2%), especially when combined with antihypertensive drugs.
Psychological symptoms: Anxiety and agitation (5%), often seen during the dose adjustment period.
Drug interactions
Taboo combination:Monoamine oxidase inhibitors (MAOIs): spaced at least 14 days apart.Serotonin drugs (such as SSRIs and tramadol): increase the risk of serotonin syndrome.
Cautious combination:
Benzodiazepines: aggravate central inhibition and require reduced dosage.
Warfarin: INR value may increase, coagulation function needs to be monitored.
CYP3A4 inhibitors (such as ketoconazole): As the blood drug concentration increases, the dosage needs to be adjusted.
Patient education and long-term management
Improvement of medication adherence
Time guidance: Take medication before bedtime to avoid drowsiness caused by daytime medication.
Dose adjustment: Emphasize slow increments and evaluate efficacy every 2 weeks.
Lifestyle intervention:Avoid drinking alcohol (exacerbating central inhibition).Be cautious when driving or operating machinery (which may affect attention in the early stages).
Long term monitoring plan
Laboratory examination:
Baseline period: blood routine, liver function, electrolytes.
Monthly: weight, blood pressure, heart rate.
Every 3 months: Blood routine (with a focus on monitoring neutrophils).
Symptom assessment:Use the PHQ-9 scale to assess depressive symptoms on a monthly basis.Record sleep quality (time to fall asleep, number of awakenings at night).
Medication discontinuation and withdrawal symptoms
Discontinuation principle: Gradually reduce dosage (50% every 3 days) to avoid sudden discontinuation.
Withdrawal symptoms:Headache (38%), fatigue (25%), insomnia (18%).Anxiety and agitation (12%), nausea (9%).
Solution:
Mild symptoms: symptomatic support (such as acetaminophen pain relief).
For those with severe symptoms: restore the original dose and slowly reduce the dosage.
Hot Tags: mirtazapine powder, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, 99 9 pure lidocaine powder, epinephrine hcl powder, Iodomethane d3, Peptide, Sapropterin Hydrochloride, Tetrahydrobiopterin BH4 Powder